The Union Cycliste Internationale (UCI) and Cycling Anti-Doping Foundation (CADF) has received the report of the Swiss Laboratory for Doping Analyses (LAD) with regards to the vial found by a spectator on the road of the latest Paris-Roubaix on April 13, 2014.
The report states that “it has been possible to highlight the presence of ibuprofen, caffeine, theophylline and quinine” in the white powder contained in this vial. It goes onto state that “None of those substances is part of the WADA prohibited list”, and concludes by saying that “no doping substance could be detected in the white powder transferred by the UCI”.
UK Anti-Doping Director of Operations Nicole Sapstead said: “A member of the public, and by consequence the Report Doping in Sport hotline, played an integral role in ensuring that this information was passed on to the appropriate authorities to be properly investigated. We applaud all those who recognised that this was the most appropriate action to take in the pursuit of clean sport."
“UK Anti-Doping acted quickly, working closely with our partners at the CADF and UCI, and we hope that fans are reassured that anti-doping organisations are collaborating on a global level to deter and detect suspicions of doping."
“Anyone with concerns, no matter what your involvement in sport, should use this as a case study and speak out by visiting www.reportdoping.com.
UCI President Brian Cookson declared: “This case is the perfect example of how good collaboration between National Anti-Doping Organizations (NADO), the CADF and the UCI makes our anti-doping programme as robust and efficient as possible. I would like to thank UK Anti-Doping for its collaboration with the CADF and the UCI in this case.”
CADF Director Francesca Rossi stated: “This investigation demonstrates perfectly the transparency and collaboration in our anti-doping programme. I am pleased with the confidence UK Anti-Doping and the UCI have shown in the CADF to conduct the operational part of this case.”
For more information:
UCI Press Officer
+41 79 198 7047
+44 7813 814 816